Nanoparticle-mediated inhibition of Yes-associated protein prevents corneal scarring after traumatic injury
Source abstract
Abstract
Corneal scars develop during the regenerative process following traumatic injuries. Verteporfin (VP), a Yes-associated protein (YAP) inhibitor, has shown promise as an antifibrotic agent, but its application to the ocular surface is limited by unfavorable physicochemical properties. Here, we developed the hyaluronic acid-verteporfin nanoparticles (HA-VP NPs) to increase the apparent solubility of VP and prolong residence on the eye, aiming to promote corneal regeneration and prevent scar formation following injuries. The HA-VP NPs effectively prevented not only the transformation of corneal stromal cells into myofibroblasts, but also the epithelial-mesenchymal transition of epithelial cells by inhibiting the translocation of YAP into the nucleus. HA-VP NPs interacted with CD44 receptors, facilitating endocytosis in corneal stromal cells and contributing to prolonged residence time in corneal defects. In a rat anterior lamellar keratoplasty model, the HA-VP NPs were retained on corneal defects for at least 4 h, resulting in excellent corneal regeneration and significant reduction in scarring.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Corneal Surgery and Treatments · Traumatic Ocular and Foreign Body Injuries · Ocular Surface and Contact Lens
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (62)
Show source-provided references
1. Nanomedicine approaches for corneal diseases10.3390/jfb6020277 ↗
2. Regenerative therapy for the cornea10.1016/j.preteyeres.2021.101011 ↗
3. A customized janus hydrogel with both anti-fibrosis and anti-infection properties for suture-free and care-free corneal injury repair10.1002/adfm.202513261 ↗
4. Biologically inspired bioactive hydrogels for scarless corneal repair10.1126/sciadv.adt1643 ↗
5. Impact of keratocyte differentiation on corneal opacity resolution and visual function recovery in Male rats10.1038/s41467-024-49008-3 ↗
6. Effect of TGF-b on ocular surface epithelial cells10.1016/j.exer.2012.11.017 ↗
7. YAP and TAZ are distinct effectors of corneal myofibroblast transformation10.1016/j.exer.2018.12.009 ↗
8. Smooth muscle a-Actin expression and myofibroblast differentiation by TGFb are dependent upon MK210.1002/jcb.21154 ↗
9. Crosstalk between Hippo and TGFβ: subcellular localization of YAP/TAZ/Smad complexes10.1016/j.jmb.2015.04.015 ↗
10. YAP promotes epithelial mesenchymal transition by upregulating Slug expression in human colorectal cancer cells
11. Epithelial-mesenchymal transition in tissue repair and fibrosis10.1007/s00441-016-2464-0 ↗
12. Topical losartan inhibits corneal scarring fibrosis and collagen type IV deposition after descemet's membrane-endothelial excision in rabbits10.1016/j.exer.2022.108940 ↗
13. Modulation of corneal wound healing after excimer laser keratomileusis using topical Mitomycin C and steroids10.1001/archopht.1991.01080080101040 ↗
14. Topical rosiglitazone is an effective anti-scarring agent in the cornea10.1371/journal.pone.0070785 ↗
15. Preventing Engrailed-1 activation in fibroblasts yields wound regeneration without scarring10.1126/science.aba2374 ↗
16. Scarless wound healing programmed by core-shell microneedles10.1038/s41467-023-39129-6 ↗
17. Active epithelial hippo signaling in idiopathic pulmonary fibrosis10.1172/jci.insight.98738 ↗
18. Selective targeting of vascular endothelial YAP activity blocks EndMT and ameliorates unilateral ureteral obstruction-induced kidney fibrosis10.1021/acsptsci.1c00010 ↗
19. Systems-based identification of the Hippo pathway for promoting fibrotic mesenchymal differentiation in systemic sclerosis10.1038/s41467-023-44645-6 ↗
20. Yes-associated protein inhibition ameliorates liver fibrosis and acute and chronic liver failure by decreasing ferroptosis and necroptosis
21. Evaluation of Verteporfin as a novel antifibrotic agent in a rabbit model of glaucoma filtration surgery10.1016/j.xops.2023.100448 ↗
22. Repurposing verteporfin and hyaluronic acid gel for ocular surface treatment to prevent corneal scarring10.1016/j.jconrel.2025.02.051 ↗
23. Lipid nanoparticles as efficient verteporfin nanocarriers for photodynamic therapy of cancer10.1039/D3MA00797A ↗
24. Photodynamic therapy with Verteporfin (Visudyne): impact on ophthalmology and visual sciences
25. Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties10.1016/j.drudis.2019.02.001 ↗
26. Ocular drug delivery: a comprehensive review10.1208/s12249-023-02516-9 ↗
27. In situ-forming, bioorthogonally cross-linked, nanocluster-reinforced hydrogel for the regeneration of corneal defects10.1021/acsnano.4c02345 ↗
28. Photoactivated growth factor release from bio-orthogonally crosslinked hydrogels for the regeneration of corneal defects
29. Supramolecular adhesive hydrogels for tissue engineering applications10.1021/acs.chemrev.1c00815 ↗
30. Subcutaneously injectable hyaluronic acid hydrogel for sustained release of donepezil with reduced initial burst release: effect of hybridization of microstructured lipid carriers and albumin10.3390/pharmaceutics13060864 ↗
31. In situ-forming collagen hydrogel crosslinked via multi-functional PEG as a matrix therapy for corneal defects10.1038/s41598-020-72978-5 ↗
32. Reproducible derivation and expansion of corneal mesenchymal stromal cells for therapeutic applications10.1167/tvst.9.3.26 ↗
33. Transforming growth Factor-β1 (TGF-β1)-Stimulated fibroblast to myofibroblast differentiation is mediated by Hyaluronan (HA)-facilitated epidermal growth factor receptor (EGFR) and CD44 Co-Localization in lipid rafts10.1074/jbc.M113.451336 ↗
34. Epithelial-mesenchymal transition in tissue repair and fibrosis10.1007/s00441-016-2464-0 ↗
35. Epithelial-mesenchymal transition and its implications for fibrosis10.1172/JCI200320530 ↗
36. YAP promotes epithelial mesenchymal transition by upregulating slug expression in human colorectal cancer cells
37. KRAS and YAP1 converge to regulate EMT and tumor survival10.1016/j.cell.2014.06.004 ↗
38. The E-Cadherin and N-Cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges10.3390/cells8101118 ↗
39. Vimentin regulates EMT induction by slug and oncogenic H-Ras and migration by governing axl expression in breast cancer10.1038/onc.2010.509 ↗
40. Epithelial-mesenchymal transitions: twist in development and metastasis10.1016/j.cell.2004.07.011 ↗
41. CD44-mediated uptake and degradation of hyaluronan10.1016/S0945-053X(01)00186-X ↗
42. Single cell transcriptomics reveals the heterogeneity of the human cornea to identify novel markers of the Limbus and Stroma10.1038/s41598-021-01015-w ↗
43. Relationship of density, depth, and surface irregularity of superficial corneal opacification with visual acuity10.1080/02713683.2023.2173786 ↗
44. Aldehyde dehydrogenase (ALDH) 3A1 expression by the human keratocyte and its repair phenotypes10.1016/j.exer.2006.05.011 ↗
45. Descemet's membrane supports corneal endothelial cell regeneration in rabbits10.1038/s41598-017-07557-2 ↗
46. Stem cells as a novel and promising source for ocular surface regeneration10.1007/s12015-011-9245-7 ↗
47. Entropy-mediated high-entropy MXenes nanotherapeutics: NIR-II-Enhanced intrinsic oxidase mimic activity to combat Methicillin-resistant Staphylococcus Aureus infection
48. Platinum nanoparticles regulated V2C MXene nanoplatforms with NIR-II enhanced nanozyme effect for photothermal and chemodynamic anti-infective therapy
49. Digital micelles of encoded polymeric amphiphiles for direct sequence reading and Ex vivo label-free quantification10.1038/s41557-022-01076-y ↗
50. Hydroxyapatite-binding albumin nanoclusters for enhancing bone tumor chemotherapy10.1016/j.jconrel.2021.12.039 ↗
51. Enhancement of the therapeutic efficacy of the MAP regimen using thiamine pyrophosphate-decorated albumin nanoclusters in Osteosarcoma treatment10.1002/btm2.10472 ↗
52. Bone tumor-homing nanotherapeutics for prolonged retention in tumor microenvironment and facilitated apoptotic process via mevalonate pathway inhibition
53. YAP/TAZ: molecular pathway and disease therapy10.1002/mco2.340 ↗
54. Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine10.1038/s41573-020-0070-z ↗
55. Molecular pathways: YAP and TAZ take center stage in organ growth and tumorigenesis10.1158/1078-0432.CCR-12-3172 ↗
56. A comparison of cellular uptake mechanisms, delivery efficacy, and intracellular fate between liposomes and extracellular vesicles10.1002/adhm.202300319 ↗
57. Multifunctional hydrogel eye drops for synergistic treatment of ocular inflammatory disease10.1021/acsnano.3c08869 ↗
58. Nanoceria-mediated cyclosporin A delivery for dry eye disease management through modulating immune−epithelial crosstalk10.1021/acsnano.3c11514 ↗
59. Hyaluronic acid-bilirubin nanomedicine-based combination chemoimmunotherapy10.1038/s41467-023-40270-5 ↗
60. Self-assembled hyaluronic acid nanoparticles for active tumor targeting10.1016/j.biomaterials.2009.09.030 ↗
61. Hyaluronic acid nanoparticles as a topical agent for treating psoriasis10.1021/acsnano.2c07843 ↗
62. Design, clinical translation and immunological response of biomaterials in regenerative medicine10.1038/natrevmats.2016.40 ↗